In any case, based on the results retrieved, the authors concluded that there was a significant interaction between the treatment with BSE and the clinical course of PCa, as the prostate-specific antigen (PSA) decreased by 50% in most patients, despite the variability in the gene expression patterns associated with the treatment. This evidence concerns the gene KLK3 and posterior cortical atrophy.